Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Detalles Bibliográficos
Main Authors:	Mueller, G, Vanderkerken, K, Russell, R, Croucher, P
Formato:	Conference item
Publicado:	2004

Títulos similares

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
por: Mueller, G, et al.
Publicado: (2004)

The Role of Myeloma Cells to Osteoclast Activation
por: Bahare Sadeghi, et al.
Publicado: (2010-01-01)

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
por: Ersek, A, et al.
Publicado: (2015)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
por: Shipman, C, et al.
Publicado: (2000)

An In Vitro Model of Murine Osteoclast-Mediated Bone Resorption
por: Xiaoyue Sun, et al.
Publicado: (2024-11-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
por: Edwards, C, et al.
Publicado: (2007)

Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
por: Leng, H
Publicado: (2019)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
por: Croucher, P, et al.
Publicado: (2002)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
por: Mabilleau, G, et al.
Publicado: (2009)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.
por: Mabilleau, G, et al.
Publicado: (2009)

Osteoprotegerin and the development of myeloma bone disease
por: Croucher, P, et al.
Publicado: (2004)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
por: Zhuang, J, et al.
Publicado: (2008)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Dongzheng Gai, et al.
Publicado: (2022-09-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Yu-Tzu Tai, et al.
Publicado: (2018-08-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
por: Tibullo eDaniele, et al.
Publicado: (2015-10-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
por: Shipman, C, et al.
Publicado: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
por: Croucher, P, et al.
Publicado: (2000)

Bisphosphonates--mechanisms of action in multiple myeloma.
por: Shipman, C, et al.
Publicado: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
por: Croucher, P, et al.
Publicado: (2003)

The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
por: Jing Fu, et al.
Publicado: (2023-07-01)

TRPV2-induced Ca2+-calcineurin-NFAT signaling regulates differentiation of osteoclast in multiple myeloma
por: Hua Bai, et al.
Publicado: (2018-10-01)

BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO
por: Mabilleau, G, et al.
Publicado: (2010)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
por: Vanderkerken, K, et al.
Publicado: (2003)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
por: Zhuang, J, et al.
Publicado: (2007)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
por: Zhuang, J, et al.
Publicado: (2012)

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids
por: Xu, K, et al.
Publicado: (2009)

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.
por: Minna Qiao, et al.
Publicado: (2015-01-01)

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
por: Maiko Matsushita, et al.
Publicado: (2015-01-01)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
por: Junling Zhuang, et al.
Publicado: (2012-01-01)

In vitro generation of mature human osteoclasts.
por: Hemingway, F, et al.
Publicado: (2011)

In vitro generation of mature human osteoclasts.
por: Hemingway, F, et al.
Publicado: (2011)

Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
por: Kudo, O, et al.
Publicado: (2002)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Liesbeth Bieghs, et al.
Publicado: (2010-01-01)

Effect of amorphous silica nanoparticles on <it>in vitro </it>RANKL-induced osteoclast differentiation in murine macrophages
por: Nagano Kazuya, et al.
Publicado: (2011-01-01)

Osteoclasts and Microgravity
por: John Kelly Smith
Publicado: (2020-09-01)

Estrogen receptor gene expression in osteoclasts loss with osteoclast maturation.
por: Oreffo, R, et al.
Publicado: (1997)

Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts
por: Zhao W, et al.
Publicado: (2025-03-01)

NK cells support osteoclast formation in vitro
por: Owen, S, et al.
Publicado: (2004)

Activated T lymphocytes support osteoclast formation in vitro.
por: Horwood, N, et al.
Publicado: (1999)

NK cells support osteoclast formation in vitro
por: Danks, L, et al.
Publicado: (2005)